The advisors DocMorris on rights offering
Baker McKenzie Switzerland – along with Baker McKenzie lawyers from the UK, US, Germany and further European jurisdictions – advised DocMorris on its rights offering with gross proceeds of CHF 208 million.
In connection with the deal, Advestra advised UBS, Bank of America, Zürcher Kantonalbank and the other members of the banking syndicate.
The proceeds will be directed at financing the planned medium-term growth in the prescription medicines (Rx) business.
In connection with the operation, the company has issued 36,182,790 new registered shares on 21 May 2025. The stocks in question went public on SIX Swiss Exchange on 22 May 2025 and settled on 26 May 2025. The capital increase was accompanied by a nominal value reduction from CHF 30.00 to CHF 0.01.
The company
Headquartered in Frauenfeld, DocMorris is an online pharmacy and healthcare specialist, with brand presence in Germany and Europe. The company employs around 1,600 people across multiple countries, and lists on the SIX Swiss Exchange under the ticker DOCM.
The Baker McKenzie team
Swiss capital markets partners Matthias Courvoisier (pictured above – left) and Yves Mauchle (pictured above – right) led the cross office Baker McKenzie team on the matter.
With regard to Baker McKenzie Switzerland (Swiss capital markets, corporate and tax), Jan Lusti, Kiara Sharifi, Jonas Zürrer, Sadia Raja, Chiara Pedrazzetti, Andrea Bolliger, and Nathan Bouvier took part to the operation.
Adam Farlow and Charles Farnsworth further contributed from Baker McKenzie London Farnsworth (US capital markets). Moreover, Paul de Pasquale and Jayshree Narendran worked from Baker McKenzie New York (US tax), while Frank Pflüger joined the team from Baker McKenzie Frankfurt (EU and German regulatory).
The Advestra team
The Advestra lineup on the matter featured Annette Weber (pictured), Thomas Reutter, Silvan Biedermann, Valérie Bayard, Sven Pinter and Jana Wildberger (all capital markets) as well as Céline Martin (tax).
